Xinpu Biotechnology

Shanghai Xinpu Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of therapeutic mRNA vaccines for oncology. The company focuses on a dual strategy involving "off-the-shelf" vaccines targeting common driver mutations, such as KRAS G12V, as well as personalized neoantigen vaccines tailored to a patient's individual mutational profile. Its lead candidates, including XP-001-V2 and XP-004, are currently undergoing Phase 1 clinical evaluation in patients with advanced solid tumors, pancreatic cancer, and lung cancer, frequently in combination with PD-1 inhibitors. Xinpu Biotechnology utilizes a proprietary mRNA-LNP delivery platform and maintains significant research collaborations with prestigious institutions like Ruijin Hospital. The company has gained international recognition for publishing groundbreaking first-in-human clinical data in high-impact journals such as Cell Research.